Overview
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Status:
Completed
Completed
Trial end date:
2004-11-01
2004-11-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:- Ages Eligible for Study: 18 Years - 60 Years
Exclusion Criteria:
- - -